QPPV.COM KNOWLEDGE ASSESSMENT

Safety Specification: Pharmacovigilance and EU Risk Management Assessment

Test your understanding of the concepts covered by Safety Specification.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which evidence strategy is most appropriate when characterising a safety concern?
Question 2 of 10 Which feature distinguishes missing information from an important potential risk?
Question 3 of 10 Which combination is required for an important identified risk?
Question 4 of 10 Which situation best illustrates an important potential risk?
Question 5 of 10 A company proposes a registry without identifying which safety concern it will address. What is the principal regulatory weakness of this proposal?
Question 6 of 10 What is the principal danger of including an excessive number of safety concerns in an RMP?
Question 7 of 10 Which documentation most directly demonstrates traceability from a safety concern to RMP actions?
Question 8 of 10 A product has several common, mild and well-characterised adverse reactions that do not materially affect its benefit-risk balance or require special management. How should they generally be treated in the Safety Specification?
Question 9 of 10 Which example is most likely to constitute clinically relevant missing information?
Question 10 of 10 Which approach best reflects the modern regulatory expectation for the scope of a Safety Specification?

Select an answer to continue.

QPPV.com